Bayer Gets Swift Review for Kerendia in Type 1 Diabetes

Why It Matters

The approval would give the first new therapy for CKD in type 1 diabetes in three decades, expanding Bayer’s revenue base while addressing a high‑unmet‑need patient segment.

Key Takeaways

• Bayer seeks FDA priority review to add T1D indication for Kerendia
• Phase 3 FINE‑ONE showed 34% UACR reduction versus 12% placebo
• Kerendia sales rose 84% to $318 million, nearing $1 billion blockbuster
• New label could boost Bayer’s pipeline amid Xarelto patent loss
• CKD affects 850 million globally; T1D patients represent 30% of CKD cases

Pulse Analysis

Bayer’s recent filing to expand Kerendia’s label to type 1 diabetes marks a rare regulatory push in the chronic kidney disease (CKD) arena. CKD touches roughly 850 million people worldwide, and about 30 % of those with type 1 diabetes eventually develop kidney impairment, a cohort that currently lacks dedicated pharmacologic options. Kerendia (finerenone), a mineralocorticoid receptor antagonist, received a priority review from the FDA, compressing the decision timeline to six months. If cleared, it would become the first new therapy in more than three decades for adults with CKD linked to type 1 diabetes, potentially reshaping standard‑of‑care protocols.

The underlying data come from the phase 3 FINE‑ONE trial, which enrolled 242 participants and demonstrated a 34 % drop in urinary albumin‑to‑creatinine ratio after six months, compared with a modest 12 % decline on placebo. The study also reported improvements in estimated glomerular filtration rate, reinforcing Kerendia’s renal protective profile. Commercially, the drug has already surged, with first‑quarter sales climbing 84 % to €274 million ($318 million) and on track to breach the $1 billion blockbuster milestone. This momentum helps Bayer offset waning revenues from Xarelto and mounting competition to its eye‑drug Eylea.

Beyond the immediate T1D indication, Bayer is eyeing a broader CKD label that would include non‑diabetic patients, based on the ongoing FIND‑CKD study. Such an expansion could unlock a sizable market, given that half of CKD sufferers do not have diabetes. For investors and clinicians, the move signals Bayer’s strategic shift toward renal and cardiovascular therapeutics, sectors that promise higher margins and longer product lifecycles. Patients stand to benefit from a therapy that addresses both kidney function and cardiovascular risk, two intertwined complications that have historically been managed with separate drug classes.